Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators.
In a recent study, the vasodilating drugs nifedipine, nitrendipine, felodipine, and hydralazine induced phalangeal defects in rabbits, when given on day 16 of pregnancy. Histologically, the changes were characterized by disturbed chondrogenesis. In order to elucidate mechanisms behind the defects, the fetal concentration of felodipine was measured, and the fetal limb plates were examined histologically, at 0, 2, 4, 8, 12, and 24 hours after single oral administration of felodipine (12 mumol/kg) on day 16 in pregnant rabbits. The effects of nifedipine, nitrendipine, and felodipine were also investigated in an in vitro system, in which chick embryonic mesenchymal limb bud cells differentiated into chondrocytes. In this system, no inhibition of chondrogenesis was observed below concentrations 3 x 10(5) M. At this concentration, unspecific cytotoxicity was found. The highest fetal concentrations of felodipine were more than 500 times lower than what was required for in vitro toxicity. Histologically, the digital areas of the limb plates showed extensive edema and dilatation of marginal sinus within 2 hours. After 8 hours, rupture of the thin-walled vessels occurred with hemorrhages. Finally, small necroses and blisters were observed. Similar early changes have been reported in experiments where digital defects were induced by clamping uterine vessels. This study thus indicates that the phalangeal defects after administration of high doses of vasodilators are secondary to pharmacological action (associated with a significant reduction in the uteroplacental blood flow), and not a direct effect on fetal chondrogenesis.
Danielsson
B R
BR
Department of Safety Assessment, AB Astra, Södertälje, Sweden.
Danielson
M
M
Reiland
S
S
Rundqvist
E
E
Dencker
L
L
Regård
C G
CG
D000014:Abnormalities, Drug-Induced / Q000473:pathology*; D000818:Animals; D002642:Chick Embryo; D005121:Extremities / Q000473:pathology; D015736:Felodipine / Q000009:adverse effects / Q000032:analysis / Q000378:metabolism; D005260:Female; D066298:In Vitro Techniques; D017880:Limb Deformities, Congenital; D008431:Maternal-Fetal Exchange; D009543:Nifedipine / Q000009:adverse effects; D009568:Nitrendipine / Q000009:adverse effects; D010920:Placenta / Q000098:blood supply* / Q000187:drug effects; D011247:Pregnancy; D011817:Rabbits; D014665:Vasodilator Agents / Q000009:adverse effects*
D014665:Vasodilator Agents; D009568:Nitrendipine; D009543:Nifedipine; D015736:Felodipine